文献速递间质性肺疾病

吡非尼酮与尼达尼布比较:CleanUP-IPF研究的事后分析

Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study.
PubMed 文献 · Chest · 2023-11-27

该研究为CleanUP-IPF试验的事后分析,纳入407例报告使用吡非尼酮(n=264)或尼达尼布(n=143)的IPF患者,比较12个月FVC下降差异。尼达尼布组12个月FVC较吡非尼酮组高106 mL(95%CI 34-178),24个月时差异减弱;两组总生存和非计划呼吸住院无显著差异。

要点

  • 尼达尼布组12个月FVC较吡非尼酮组高106 mL(95%CI 34-178)。
  • 吡非尼酮组冠心病史比例高于尼达尼布组(34.1% vs 20.3%)。
  • 两组总生存和非计划呼吸住院无显著差异。

核心结论

  • 在CleanUP-IPF试验的事后分析中,使用尼达尼布的IPF患者12个月FVC下降较吡非尼酮组慢。

研究设计与样本

  • CleanUP-IPF试验(NCT02759120)的事后分析,513例随机化IPF患者中407例报告使用吡非尼酮(n=264,65%)或尼达尼布(n=143,35%)。
  • 采用线性混合效应模型(随机截距和斜率)分析FVC随时间变化,并校正年龄、性别、吸烟史、冠心病史、基线FVC和12个月样条项。
  • 采用Cox回归模型分析生存和非计划呼吸住院,校正年龄、性别、吸烟史、冠心病史、基线FVC和DLCO。

主要发现

  • 尼达尼布组12个月访视时FVC高于吡非尼酮组,平均差异106 mL(95%CI 34-178)。
  • 该差异在24个月研究访视时减弱。
  • 吡非尼酮组冠心病史比例高于尼达尼布组(34.1% vs 20.3%)。
  • 两组总生存和非计划呼吸住院无显著差异。

临床怎么用

  • 对于IPF患者,选择抗纤维化药物时可参考12个月FVC变化差异,尼达尼布组FVC下降较慢。
  • 需结合患者冠心病史等合并症个体化选择抗纤维化药物。

局限性

  • 本研究为事后分析,抗纤维化药物使用非随机分配。
  • 吡非尼酮组冠心病史比例高于尼达尼布组,可能存在混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antifibrotics are effective in slowing FVC decline in idiopathic pulmonary fibrosis (IPF). However, whether antifibrotic type is differentially associated with FVC decline remains inconclusive. RESEARCH QUESTION: Are there significant differences in 12-month FVC decline between pirfenidone and nintedanib? STUDY DESIGN AND METHODS: A post hoc analysis was performed using the Clinical Efficacy of Antimicrobial Therapy Strategy Using Pragmatic Design in IPF (CleanUP-IPF) trial (No. NCT02759120). Participants who reported using pirfenidone or nintedanib on enrollment into the trial were in the primary analysis. Spirometry was scheduled at baseline and the 12- and 24-month study visits. Linear mixed-effects models with random intercept and slope were used to examine changes in FVC over time. Models were adjusted for age, sex, smoking history, coronary artery disease history, baseline FVC, and 12-month spline term. Survival and nonelective respiratory hospitalization by antifibrotic type were determined using Cox regression models with adjustment for age, sex, smoking history, coronary artery disease history, and baseline FVC and diffusing capacity for carbon monoxide. RESULTS: Out of the 513 participants with IPF randomized in the CleanUP-IPF trial, 407 reported using pirfenidone (n = 264, 65%) or nintedanib (n = 143, 35%). The pirfenidone group had more participants with a history of coronary artery disease than the nintedanib group (34.1% vs 20.3%, respectively). Patients treated with nintedanib had a higher 12-month visit FVC than patients treated with pirfenidone (mean difference, 106 mL; 95% CI, 34-178). This difference was attenuated at the 24-month study visit. There were no significant differences in overall survival and nonelective respiratory hospitalization between the pirfenidone- and nintedanib-treated groups. INTERPRETATION: Patients with IPF who used nintedanib had a slower 12-month FVC decline than pirfenidone in a post hoc analysis of a clinical trial.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Kim JS, Murray S, Yow E, et al. Comparison of Pirfenidone and Nintedanib: Post Hoc Analysis of the CleanUP-IPF Study. Chest. 2023. PMID: 38030064. doi:10.1016/j.chest.2023.11.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。